JCB, Volume 21, Number 4, 2015 Commentary Vol.21 No. 4 (2015) US Supreme Court’s Decision on the Patent Ineligibility of Human Genes - BRCA1/BRCA2 as Products of Nature Ananda Mohan Chakrabarty Commentary Vol.21 No. 4 (2015) Flavonoids – World Healthiest Gift for the Benefit of Human Health Abhishek Kumar Yadav Flavonoids are one of the major nutrient families recognized to scientists, and comprise over 6,000 already recognized family members. A number of the best - recognized flavonoids include Commentary Vol.21 No. 4 (2015) Undermining Patient Values: The ASCO Value in Cancer Care Task Force Framework Peter J. Pitts As stated in a recent article in the Journal of Clinical Oncology, ASCO established a Value in Cancer Care Task Force, with the goal of “developing a framework for comparing the rel Article Vol.21 No. 4 (2015) Investment in Life Sciences in Scotland: Challenges and Opportunities Andrew Henderson As the global life sciences industry changes, the most successful regions in attracting inward investment will be those that evolve and adapt to provide the most attractive offer. In Scot Article Vol.21 No. 4 (2015) Crowdfunding: A New Untapped Opportunity for Biotechnology Start-ups? Sholeh Azar Crowdfunding is an evolving popular Internet-based process used to raise funding that has been employed by a few start-ups in the biotechnology industry. To solicit funding, companies pro Article Vol.21 No. 4 (2015) EmergingCo: A Virtual “South-South†Biotech Model ajay gautam The article proposes a “virtual†biotech model for the emerging markets - termed EmergingCo - and develops a comparative financial model to argue that such a virtual Legal and Regulatory Updates Vol.21 No. 4 (2015) The FDA's Quality Revolution Peter J. Pitts Let it be said that the spark that ignited the flame was when FDA leadership asked, “Do we know enough about the quality of drugs that are sold in the United States.â€In Legal and Regulatory Updates Vol.21 No. 4 (2015) Biosimilars in Brazil: developments in 2015 and business perspectives Denise Golgher Brazil is looking into foreign technology to foster innovation in the country’s industrial health complex. Biological plants are being built and partnerships with multinationals ha
